CN104474440A - 用于治疗仔猪营养不良性贫血的药物组合物及其制备方法 - Google Patents
用于治疗仔猪营养不良性贫血的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN104474440A CN104474440A CN201410694360.6A CN201410694360A CN104474440A CN 104474440 A CN104474440 A CN 104474440A CN 201410694360 A CN201410694360 A CN 201410694360A CN 104474440 A CN104474440 A CN 104474440A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- radix
- fructus
- pharmaceutical composition
- anemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 44
- 238000011282 treatment Methods 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 208000036654 deficiency anemia Diseases 0.000 title abstract description 5
- 210000000582 semen Anatomy 0.000 claims abstract description 42
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 23
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 23
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 21
- 241001556408 Ventilago leiocarpa Species 0.000 claims abstract description 20
- 210000003038 endothelium Anatomy 0.000 claims abstract description 20
- 235000008434 ginseng Nutrition 0.000 claims abstract description 19
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 18
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 57
- 208000007502 anemia Diseases 0.000 claims description 44
- 239000000843 powder Substances 0.000 claims description 31
- 239000000463 material Substances 0.000 claims description 30
- 235000016709 nutrition Nutrition 0.000 claims description 28
- 230000035764 nutrition Effects 0.000 claims description 28
- 108010052008 colla corii asini Proteins 0.000 claims description 23
- 241000382353 Pupa Species 0.000 claims description 22
- 229910000805 Pig iron Inorganic materials 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 239000006071 cream Substances 0.000 claims description 17
- 239000008187 granular material Substances 0.000 claims description 17
- 239000009636 Huang Qi Substances 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 15
- 238000010992 reflux Methods 0.000 claims description 14
- 238000005325 percolation Methods 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 206010013786 Dry skin Diseases 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000013521 mastic Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- 229960004793 sucrose Drugs 0.000 claims description 4
- 241000208340 Araliaceae Species 0.000 claims 3
- 239000008280 blood Substances 0.000 abstract description 63
- 210000004369 blood Anatomy 0.000 abstract description 62
- 230000000694 effects Effects 0.000 abstract description 59
- 210000000952 spleen Anatomy 0.000 abstract description 55
- 239000003814 drug Substances 0.000 abstract description 35
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract description 27
- 229940079593 drug Drugs 0.000 abstract description 18
- 238000005728 strengthening Methods 0.000 abstract description 12
- 230000008901 benefit Effects 0.000 abstract description 7
- 241000255789 Bombyx mori Species 0.000 abstract description 6
- 229910052742 iron Inorganic materials 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 5
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 abstract description 5
- 244000141331 Amomum villosum Species 0.000 abstract 1
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 241000092665 Atractylodes macrocephala Species 0.000 abstract 1
- 241000218993 Begonia Species 0.000 abstract 1
- 240000004307 Citrus medica Species 0.000 abstract 1
- 241001289529 Fallopia multiflora Species 0.000 abstract 1
- 108010010803 Gelatin Proteins 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 abstract 1
- 235000011613 Pinus brutia Nutrition 0.000 abstract 1
- 241000018646 Pinus brutia Species 0.000 abstract 1
- 241001080798 Polygala tenuifolia Species 0.000 abstract 1
- 241000206609 Porphyra Species 0.000 abstract 1
- 241001221020 Smilax riparia Species 0.000 abstract 1
- 241000270708 Testudinidae Species 0.000 abstract 1
- 241000209140 Triticum Species 0.000 abstract 1
- 235000021307 Triticum Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 239000003640 drug residue Substances 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 239000008273 gelatin Substances 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 235000011852 gelatine desserts Nutrition 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 description 35
- 210000004185 liver Anatomy 0.000 description 33
- 230000007812 deficiency Effects 0.000 description 32
- 210000002784 stomach Anatomy 0.000 description 28
- 235000009508 confectionery Nutrition 0.000 description 27
- 230000006870 function Effects 0.000 description 25
- 230000001737 promoting effect Effects 0.000 description 24
- 210000004072 lung Anatomy 0.000 description 23
- 210000002216 heart Anatomy 0.000 description 22
- 241000282898 Sus scrofa Species 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 210000003205 muscle Anatomy 0.000 description 18
- 206010011224 Cough Diseases 0.000 description 17
- 208000002193 Pain Diseases 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 240000004371 Panax ginseng Species 0.000 description 15
- 210000000988 bone and bone Anatomy 0.000 description 15
- 239000007789 gas Substances 0.000 description 15
- 230000036407 pain Effects 0.000 description 15
- 206010012735 Diarrhoea Diseases 0.000 description 14
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 14
- 230000017531 blood circulation Effects 0.000 description 14
- 206010022437 insomnia Diseases 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 206010010774 Constipation Diseases 0.000 description 13
- 206010003549 asthenia Diseases 0.000 description 13
- 208000001848 dysentery Diseases 0.000 description 13
- 206010030113 Oedema Diseases 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 206010033557 Palpitations Diseases 0.000 description 11
- 206010037660 Pyrexia Diseases 0.000 description 11
- 208000002173 dizziness Diseases 0.000 description 11
- 235000013305 food Nutrition 0.000 description 11
- 241000411851 herbal medicine Species 0.000 description 11
- 239000002398 materia medica Substances 0.000 description 11
- 208000008454 Hyperhidrosis Diseases 0.000 description 10
- 230000002269 spontaneous effect Effects 0.000 description 10
- 206010010904 Convulsion Diseases 0.000 description 9
- 208000032843 Hemorrhage Diseases 0.000 description 9
- 230000004087 circulation Effects 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 231100000614 poison Toxicity 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 230000035900 sweating Effects 0.000 description 9
- 230000035922 thirst Effects 0.000 description 9
- 238000010792 warming Methods 0.000 description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 230000003014 reinforcing effect Effects 0.000 description 8
- 208000006820 Arthralgia Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000010839 body fluid Substances 0.000 description 7
- 230000001914 calming effect Effects 0.000 description 7
- 230000036461 convulsion Effects 0.000 description 7
- 230000001603 reducing effect Effects 0.000 description 7
- 235000019640 taste Nutrition 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 208000031971 Yin Deficiency Diseases 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000000038 chest Anatomy 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000000994 depressogenic effect Effects 0.000 description 6
- 239000007952 growth promoter Substances 0.000 description 6
- 230000036565 night sweats Effects 0.000 description 6
- 206010029410 night sweats Diseases 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 239000002574 poison Substances 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000027939 micturition Effects 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 208000019255 Menstrual disease Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 201000004792 malaria Diseases 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 235000015961 tonic Nutrition 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- 230000008736 traumatic injury Effects 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 206010006895 Cachexia Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- 208000036119 Frailty Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010019468 Hemiplegia Diseases 0.000 description 3
- 206010022971 Iron Deficiencies Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 206010042434 Sudden death Diseases 0.000 description 3
- 208000009205 Tinnitus Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000001467 acupuncture Methods 0.000 description 3
- 239000003159 antacid agent Substances 0.000 description 3
- 230000001773 anti-convulsant effect Effects 0.000 description 3
- 230000004596 appetite loss Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000001465 calcium Nutrition 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 208000019902 chronic diarrheal disease Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 208000026500 emaciation Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 235000021266 loss of appetite Nutrition 0.000 description 3
- 208000019017 loss of appetite Diseases 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 239000004575 stone Substances 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000886 tinnitus Toxicity 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 239000000052 vinegar Substances 0.000 description 3
- 235000021419 vinegar Nutrition 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 235000016804 zinc Nutrition 0.000 description 3
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 206010000242 Abortion threatened Diseases 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 241000255791 Bombyx Species 0.000 description 2
- 206010056377 Bone tuberculosis Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000008967 Enuresis Diseases 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 206010018498 Goitre Diseases 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 208000015817 Infant Nutrition disease Diseases 0.000 description 2
- 206010061245 Internal injury Diseases 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000009360 Osteoarticular Tuberculosis Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 208000001203 Smallpox Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 208000005985 Threatened Abortion Diseases 0.000 description 2
- 241000870995 Variola Species 0.000 description 2
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 230000001458 anti-acid effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 2
- 208000002894 beriberi Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000010437 erythropoiesis Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 201000003872 goiter Diseases 0.000 description 2
- 239000008616 guibi-tang Substances 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 229940025878 hesperidin Drugs 0.000 description 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 230000003867 tiredness Effects 0.000 description 2
- 208000016255 tiredness Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000001113 umbilicus Anatomy 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- GKAJCVFOJGXVIA-UHFFFAOYSA-N 4'-methoxy-3,3',5-stilbenetriol 3-glucoside Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(O)=CC(OC2C(C(O)C(O)C(CO)O2)O)=C1 GKAJCVFOJGXVIA-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 102100027265 Aldo-keto reductase family 1 member B1 Human genes 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002953 Aphonia Diseases 0.000 description 1
- 241000707825 Argyrosomus regius Species 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000009084 Cold Injury Diseases 0.000 description 1
- 241001550206 Colla Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010063827 Extramedullary haemopoiesis Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 229910015191 FeOFe2O3 Inorganic materials 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241001506304 Kadsura japonica Species 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010027540 Microcytosis Diseases 0.000 description 1
- 101100288498 Mus musculus Large1 gene Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- MAYJEFRPIKEYBL-OASIGRBWSA-N Obacunone Chemical compound C=1([C@@H]2OC(=O)[C@H]3O[C@@]43[C@]3(C)C(=O)C[C@H]5C(C)(C)OC(=O)C=C[C@]5(C)[C@H]3CC[C@]42C)C=COC=1 MAYJEFRPIKEYBL-OASIGRBWSA-N 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241000736919 Pelodiscus sinensis Species 0.000 description 1
- 206010034240 Pelvic congestion Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 206010044278 Trace element deficiency Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 208000022440 X-linked sideroblastic anemia 1 Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- QVYYOKWPCQYKEY-UHFFFAOYSA-N [Fe].[Co] Chemical compound [Fe].[Co] QVYYOKWPCQYKEY-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000003796 chancre Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 235000013495 cobalt Nutrition 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 229940097267 cobaltous chloride Drugs 0.000 description 1
- 230000002595 cold damage Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229940056319 ferrosoferric oxide Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000005242 forging Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 230000002984 haematinic effect Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 208000023513 hiccough Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- UCNNJGDEJXIUCC-UHFFFAOYSA-L hydroxy(oxo)iron;iron Chemical compound [Fe].O[Fe]=O.O[Fe]=O UCNNJGDEJXIUCC-UHFFFAOYSA-L 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- PVFSDGKDKFSOTB-UHFFFAOYSA-K iron(3+);triacetate Chemical compound [Fe+3].CC([O-])=O.CC([O-])=O.CC([O-])=O PVFSDGKDKFSOTB-UHFFFAOYSA-K 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- KXMTXZACPVCDMH-UHFFFAOYSA-N methyl 4-[5-(hydroxymethyl)-7-methoxy-1,3-benzodioxol-4-yl]-7-methoxy-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1CO KXMTXZACPVCDMH-UHFFFAOYSA-N 0.000 description 1
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 201000006451 norwegian scabies Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- VSLDMVSILHVDSR-UHFFFAOYSA-N obacunone Natural products CC1(C)OC(=O)C=CC2(C)C1CC(=O)C3(C)C2CCC4(C)C(OC(=O)C5OC345)c6occc6 VSLDMVSILHVDSR-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- OISYIJRGMYJBRH-UHFFFAOYSA-N physcione Natural products COc1cc(O)c2C(=O)c3ccc(O)cc3C(=O)c2c1 OISYIJRGMYJBRH-UHFFFAOYSA-N 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- GKAJCVFOJGXVIA-QGLKVJOYSA-N rhaponticin Natural products COc1ccc(C=Cc2cc(O)cc(O[C@@H]3O[C@@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1O GKAJCVFOJGXVIA-QGLKVJOYSA-N 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- GKAJCVFOJGXVIA-DXKBKAGUSA-N trans-rhaponticin Chemical compound C1=C(O)C(OC)=CC=C1\C=C\C1=CC(O)=CC(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 GKAJCVFOJGXVIA-DXKBKAGUSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- -1 triterpenoid compound Chemical class 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000000112 undernutrition Nutrition 0.000 description 1
- 125000005314 unsaturated fatty acid group Chemical group 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种用于治疗仔猪营养不良性贫血的药物组合物及其制备方法,其中,药物组合物包括以下原料药材:甘草、茯神、远志、酸枣仁、木香、龙眼肉、大枣、生铁落、磁石、乌梅、五味子、蚕蛹、紫菜、龟甲、鳖甲、浮小麦、海螵蛸、香橼、核桃仁、松子、鸡内金、熟地、制何首乌、阿胶、砂仁、翼核果、一点血。还包括白术、人参、黄芪、当归、桑鳸、牛尾菜。本发明的药物组合物,治疗仔猪营养不良性贫血,补气养血、健脾助运、益肾填精生髓同时,能够增强其抵抗能力,在治疗仔猪营养不良性贫血方面具有功专效宏、选药精当、质优价廉、安全适用、无药物残留等优势特点。
Description
技术领域
本发明涉及动物中药制剂技术领域,尤其涉及一种用于治疗仔猪营养不良性贫血的药物组合物及其制备方法。
背景技术
仔猪营养性贫血(Nutritional Anemia of Piglet)是指5~28d内哺乳仔猪由于营养不足及微量元素缺乏,特别是铁的缺乏而引起的贫血,临床上以可视粘膜色淡,轻度黄染或苍白;循环血液中红细胞数量下降,血红蛋白显著减少等为特征,又称为缺铁性贫血或者小细胞低色素性贫血。多发生于寒冷的冬末、春初季节的舍饲仔猪,特别是猪舍以木板或水泥为地面而不采取补铁措施的集约化养猪场。本病在一定地区具有群发性,发病率、死亡率较高,且每年都可能发生,给养猪业造成严重的经济损失。
病因:生理性病因:主要是铁不足或缺乏,仔猪出生后头几周,生长发育迅速,全血容量增长快,每天需铁7~15mg,而母乳供给的铁每天仅为1mg,于是动用体内极其微薄的贮存铁(约为40~47mg)。而此期仔猪若生长在以水泥或木板为地面的猪舍内不能与土壤接触,失去了对铁的摄取来源,同时又没有采取人工补铁措施,而使仔猪缺铁严重;加上仔猪出生后7d内胃液缺乏盐酸,获得的铁就更少了,结果血红蛋白合成不足而出现生理性贫血。条件性病因:仔猪补饲日粮中碳酸钙和锰的含量过多可以引起条件性缺铁和贫血,这主要是由于碳酸钙和锰都对铁的吸收具有拮抗作用。当日粮中蛋白质、铜、钴、锌、维生素B12、叶酸、烟酸、硫胺素、核黄素等缺乏时,可引起或促进仔猪营养性贫血的发生。磷酸、植酸、鞣酸、草酸等均能与铁结合,阻碍铁的吸收,日粮中这些物质的含量过高,也可促进本病的发生。其他:此外,环境因素如猪舍空气不流通、粉尘多、阴湿、密养等均能加重贫血。如果仔猪摄入了有毒、含生物碱的饲料和多次或长期使用某种药物(如国家规定食品动物禁用的氯霉素)也会加速贫血的发生。
危害:体内绝大部分铁用于合成血红蛋白,因此缺铁将导致血红蛋白含量下降和红细胞生成减少而发生贫血。贫血持续到一定时期便会破坏机体的氧化还原过程,同时仔猪的消化吸收机能减弱,加重了贫血的发生,进而因机体免疫性反应降低诱发消化系统和呼吸器官疾病等,死亡率可达10%~15%。
临床症状:病猪精神沉郁,离群伏卧,食欲减退,被毛逆立,缺乏光泽,生长缓慢或停止。体温不高,多伴腹泻。可视粘膜色淡,轻度黄染或苍白。光照耳壳呈灰白色,几乎见不到明显的血管,针刺也很少出血。呼吸增数,脉搏急速,可听到贫血性心内杂音;轻微运动则心搏动强盛,喘息不止。头和前躯可发生水肿,有时发生膈痉挛。有的仔猪外观很肥胖,生长发育也较快,可在奔跑中突然死亡。有的仔猪外观消瘦,便秘下痢交替出现,异嗜,衰竭;腹壁卷缩,其体型呈橄榄状。
病理变化:肝脏脂肪变形且肿大,呈淡灰色,有时有出血点。血液稀薄呈水样、凝固性差;肌肉色泽变淡,特别是臀肌和心肌呈现出典型的贫血变化。脾脏肿大,被膜增厚,色浅,质地稍结实。肾脏实质变性,呈灰白色,被膜易剥离,切面皮质和髓质界限清楚。腹腔、胸腔、心包腔积液,心脏扩张,心外膜有小点出血。肺水肿,间质明显,切面有渗出液溢出。肠系膜淋巴结水肿、淤血;胃和肠腔空虚,其粘膜有灶性病变。
组织学检查:骨髓中红细胞生成加强,在肝脏、脾脏及淋巴结有髓外造血功能。
预防:加强妊娠后期和哺乳母猪的饲养管理,增加哺乳仔猪外源性铁剂的供给。妊娠后期和哺乳母猪添加营养均衡保健产品“牲命1号”,并适当增加青绿多汁饲料,保证充足高质的母乳供给。方法为:右旋糖酐铁2ml深部肌肉注射,7d后再注射1ml;葡聚糖铁钴深部肌注,每次2ml,重症贫血者隔2d同等剂量重复1次。现有的治疗方法,一方面效果不理想,另一方面也会造成毒性物质存留。
营养不良性贫血属于中兽医虚劳范畴。治疗原则:对于虚劳的治疗,以补益为基本原则。正如《素问·三部九候论》说:“虚则补之。”在进行补益的时候,一是必须根据病理属性的不同,分别采取益气、养血、滋阴、温阳的治疗方药;二是要密切结合五脏病位的不同而选方用药,以加强治疗的针对性。在应用补益这个基本原则治疗虚劳的时候,应注意以下三点:①重视补益脾肾在治疗虚劳中的作用。以脾胃为后天之本,为气血生化之源,脾胃健运,五脏六腑、四肢百骸方能得以滋养。肾为先天之本,寓元阴元阳,为生命的本元。重视补益脾肾,先后天之本不败,则能促进各脏虚损的恢复。②对于虚中夹实及兼感外邪者,当补中有泻,扶正祛邪。从辩证的关系看,祛邪亦可起到固护正气的作用,防止因邪恋而进一步损伤正气。③虚劳的病程较长,影响的因素较多,要将药物治疗与饮食调养及生活调摄密切结合起来,方能收到更好的治疗效果。
发明内容
本发明所要解决的技术问题在于,提供一种用于治疗仔猪营养不良性贫血的药物组合物及制备方法,该药物组合物补气养血、健脾助运、益肾填精生髓,治疗仔猪营养不良性贫血具有起效快、疗效确切、安全性高、无毒副作用。治愈率高的同时,无污染,治愈后不易复发,成本价低廉,还能够保证仔猪的生长发育。
为了解决上述技术问题,本发明提供了一种用于治疗仔猪营养不良性贫血的药物组合物,其中,所述药物组合物包括以下原料药材:甘草、茯神、远志、酸枣仁、木香、龙眼肉、大枣、生铁落、磁石、乌梅、五味子、蚕蛹、紫菜、龟甲、鳖甲、浮小麦、海螵蛸、香橼、核桃仁、松子、鸡内金、熟地、制何首乌、阿胶、砂仁、翼核果、一点血。
其中,所述药物组合物中各原料药材的重量份数为:甘草10-25重量份、茯神10-20重量份、远志10-15重量份、酸枣仁10-25重量份、木香5-8重量份、龙眼肉15-26重量份、大枣20-30重量份、生铁落10-18重量份、磁石10-15重量份、乌梅10-14重量份、五味子10-20重量份、蚕蛹13-26重量份、紫菜20-30重量份、龟甲7-12重量份、鳖甲6-12重量份、浮小麦10-20重量份、海螵蛸12-23重量份、香橼10-20重量份、核桃仁20-30重量份、松子18-24重量份、鸡内金10-19重量份、熟地12-23重量份、何首乌13-20重量份、阿胶25-35重量份、砂仁10-16重量份、翼核果12-24重量份、一点血10-20重量份。
其中,所述药物组合物中各原料药材的重量份数为:甘草25重量份、茯神20重量份、远志15重量份、酸枣仁25重量份、木香8重量份、龙眼肉26重量份、大枣30重量份、生铁落18重量份、磁石15重量份、乌梅14重量份、五味子20重量份、蚕蛹26重量份、紫菜30重量份、龟甲12重量份、鳖甲12重量份、浮小麦20重量份、海螵蛸23重量份、香橼20重量份、核桃仁30重量份、松子24重量份、鸡内金19重量份、熟地23重量份、何首乌20重量份、阿胶35重量份、砂仁16重量份、翼核果24重量份、一点血20重量份。
其中,所述药物组合物还包括白术、人参、黄芪、当归、桑鳸、牛尾菜。
其中,所述药物组合物中各原料药材的重量份数为:甘草10-25重量份、茯神10-20重量份、远志10-15重量份、酸枣仁10-25重量份、木香5-8重量份、龙眼肉15-26重量份、大枣20-30重量份、生铁落10-18重量份、磁石10-15重量份、乌梅10-14重量份、五味子10-20重量份、蚕蛹13-26重量份、紫菜20-30重量份、龟甲7-12重量份、鳖甲6-12重量份、浮小麦10-20重量份、海螵蛸12-23重量份、香橼10-20重量份、核桃仁20-30重量份、松子18-24重量份、鸡内金10-19重量份、熟地12-23重量份、何首乌13-20重量份、阿胶25-35重量份、砂仁10-16重量份、翼核果12-24重量份、一点血10-20重量份、白术10-18重量份、人参12-16重量份、黄芪10-15重量份、当归13-20重量份、桑鳸10-20重量份、牛尾菜14-20重量份。
其中,所述药物组合物中各原料药材的重量份数为:甘草25重量份、茯神20重量份、远志15重量份、酸枣仁25重量份、木香8重量份、龙眼肉26重量份、大枣30重量份、生铁落18重量份、磁石15重量份、乌梅14重量份、五味子20重量份、蚕蛹26重量份、紫菜30重量份、龟甲12重量份、鳖甲12重量份、浮小麦20重量份、海螵蛸23重量份、香橼20重量份、核桃仁30重量份、松子24重量份、鸡内金19重量份、熟地23重量份、何首乌20重量份、阿胶35重量份、砂仁16重量份、翼核果24重量份、一点血20重量份、白术18重量份、人参16重量份、黄芪15重量份、当归20重量份、桑鳸20重量份、牛尾菜20重量份。
为了解决上述技术问题,本发明还提供了一种所述药物组合物的制备方法,其中,所述药物组合物的剂型为散剂,其制备方法包括以下步骤:
第一步,将所述原料药材按比例混合,加入相对于混合物质量3~5倍的醇浓度为80~90%的乙醇,加热回流1~3小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量1~2倍的醇浓度为80~90%的乙醇,加热回流1~3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1~2小时,粉碎,过筛,获得300目~400目的超微细粉;
第三步,在将第二步获得的超微细粉中加入相对于其质量2~4倍的淀粉,混合,获得散剂。
其中,所述药物组合物的剂型为颗粒剂,其制备方法包括以下步骤:
步骤一:将所述原料药材按所述比例混合,加相对于混合物3~6倍的醇浓度为84%~90%的乙醇,加热至沸腾回流2~4小时,过滤,采用渗漉法以每分钟1~2ml的速度缓缓渗漉,收集渗漉液,随后在真空度0.06~0.09Mpa下减压浓缩至55~60℃时相对密度为1.04~1.12的膏体,喷雾干燥,喷雾干燥机的进风温度165~175℃、出风温度80~85℃,随后粉碎成粉末,制成干膏粉;
步骤二:在获得的干膏粉中加入相对于干膏粉质量0.1~0.3倍的蔗糖粉和0.1~0.3倍的糊精,制成颗粒,于45~50℃干燥,获得颗粒剂。
本发明的有益效果是:该药物组合物治疗仔猪营养不良性贫血,具有补气养血、健脾助运、益肾填精生髓的功效,治疗仔猪营养不良性贫血具有起效快、疗效确切、安全性高、无毒副作用。治愈率高的同时,无污染,治愈后不易复发,成本价低廉,还能够保证仔猪的生长发育。
具体实施方式
针对患仔猪营养不良性贫血出现的相应症状,本发明提供了一种具有可调理猪脾胃功能,治疗疗程短、效果较好、残留量低的同时可增强免疫力及抵抗能力,绿色无污染的药物组合物及其制备方法。
其中中药组合物包括:甘草、茯神、远志、酸枣仁、木香、龙眼肉、大枣、生铁落、磁石、乌梅、五味子、蚕蛹、紫菜、龟甲、鳖甲、浮小麦、海螵蛸、香橼、核桃仁、松子、鸡内金、熟地、何首乌、阿胶、砂仁、翼核果、一点血。还包括白术、人参、黄芪、当归、桑鳸、牛尾菜。本方剂配伍合理、严谨,以补气养血、健脾助运、益肾填精生髓治疗仔猪营养不良性贫血,能得到理想的效果。本方以归脾汤为基础,进行辨证论治,加减化裁,其方中白术、人参、黄芪、当归、炙甘草、茯神、远志、酸枣仁、木香、龙眼肉、大枣、翼核果、一点血、桑鳸、牛尾菜为归脾汤内药物,该方补益心脾、益气养血;龙眼肉、大枣、生铁落、磁石补充铁剂;五味子、蚕蛹、紫菜、龟甲、鳖甲、浮小麦、海螵蛸、核桃仁、松子、熟地、何首乌、阿胶、益肾固精生髓;香橼、鸡内金、砂仁理气消食,防止诸药碍胃之性。纵观全方,配伍严谨。为治疗仔猪营养不良性贫血有良好的作用。
所述药物组合物中各组分药理如下:
甘草:味甘,性平,无毒。可治五脏六腑寒热邪气,坚筋骨,长肌肉,倍气力,解毒,久服轻身延年。生用泻火热,熟用散表寒,去咽痛,除邪热,缓正气,养阴血,补脾胃,润肺。炙甘草,长于温中,以甘温益气,缓急止痛力强。用于脾虚胃弱,心悸脉结代等。现代研究表明,甘草有类似肾上腺皮质激素样作用。
茯神:甘、淡;归心、脾经。《药性论》:“主惊痫,安神定志,补劳乏;主心下急痛坚满,小肠不利。”《药品化义》:“茯神,其体沉重,重可去怯,其性温补,补可去弱。”功用宁心、安神、利水。用于心虚惊悸,健忘,失眠,惊痫,小便不利。
远志:苦、辛,微温;归心、肾、肺经。《神农本草经》:“主咳逆伤中,补不足,除邪气,利九窍,益智慧,耳目聪明,不忘,强志倍力。”《日华子本草》:“主膈气惊魇,长肌肉,助筋骨,妇人血噤失音,小儿客忤。”安神益智,祛痰,消肿失眠多梦,健忘惊悸,神志恍惚。失眠多梦,心悸怔忡,健忘。癫痫惊狂,痉挛抽搐,痈疽疮毒。现代药理研究表明,远志木质部溶血作用较皮部低。全远志、远志皮、远志心在同剂量时均可以加强催眠作用;抗惊厥作用以全远志最强,远志皮次之,远志心无效;溶血作用和急毒实验以远志皮最强,全远志次之,远志心最弱;全远志与去心远志比较祛痰作用不减弱。
酸枣仁:甘、酸,性平。归心经,脾经,肝经,胆经。《神农本草经》:“补中益肝,坚筋骨,助阴气,皆酸枣仁之功也。”《本经》:“主心腹寒热,邪结气聚,四肢酸疼,湿痹。”《别录》:“主烦心不得眠,脐上下痛,血转久泄,虚汗烦渴,补中,益肝气,坚筋骨,助阴气,令人肥健。”《药性论》:“主筋骨风,炒末作汤服之。功用”养肝,宁心,安神,敛汗。有镇静、催眠、镇痛、抗惊厥作用;有一定的降压作用;对子宫有兴奋作用。用于阴血不足,心悸怔忡,失眠健忘;体虚多汗。
木香:辛苦,寒。入肺、胃经。行气,解毒,消肿。《唐本草》:"主积聚。诸毒热肿、蛇毒,水摩为泥封之,日三、四;疗疔肿大效。"《草木便方》:"发表,除风。(治)风湿瘫痪,腰脚疼痛,跌打损伤。"行气,解毒,消肿。治胸腹胀痛,痧症,肠炎下痢,高血压,疝气,蛇咬毒,痈肿,疔疮,皮肤瘙痒或湿烂。
龙眼肉:养血安神。用于气血不足、心悸怔忡、健忘失眠、血虚萎黄。《滇南本草》:“养血安神,长智敛汗,开胃益脾。”《泉州本草》:“壮阳益气,补脾胃。治妇人产后浮肿,气虚水肿,脾虚泄泻。补益心脾,”养血安神。用于气血不足、心悸怔忡、健忘失眠、血虚萎黄。龙眼所含糖分量很高,为易消化吸收的单糖,可以被人体直接吸收,故体弱贫血,年老体衰,久病体虚,经常吃些龙眼是很有补益作用;妇女产后,龙眼也是重要的调补食品。因含铁及维生素B2很丰富,可以减轻子宫收缩及宫体下垂感。
大枣:味甘,性温,入脾、胃经。具有补气健脾、养血安神、调和营卫、缓和药性的作用,用于脾胃虚弱,体倦乏力,食少便溏,气血不足,头痛发热,汗出热风等证,大枣具有增强肌力的作用,具有增加血清总蛋白和白蛋白的功能。红枣所含有的环磷酸腺苷,是人体细胞能量代谢的必需成分,能够增强肌力、消除疲劳、扩张血管、增加心肌收缩力、改善心肌营养,对防治心血管系统疾病有良好的作用;红枣对慢性肝炎、肝硬化、贫血、过敏性紫癜等病症有较好疗效;红枣含有三萜类化合物及环磷酸腺苷,有较强的抗癌、抗过敏作用。大枣能润心肺、止咳、补五脏、治虚损、除肠胃癖气,还能安中养脾、平胃气、通九窍、助十二经等。
生铁落:为生铁煅至红赤,外层氧化时被锤落的铁屑。取煅铁时打下之铁落,去其煤土杂质,洗净,晒干。或煅后醋淬用。药性辛、凉。归肝、心经。功效平肝镇惊。应用1.癫狂。本品辛凉质重,善于平肝,木平则火降,故曰下气疾速,气即火也。2.易惊善怒,失眠。3.疮疡肿毒。4.关节酸痛,扭伤疼痛。1.《神农本草经》:“主风热,恶疮,疡,疽疮,痂疥,气在皮肤中。”2.《日华子本草》:“治惊邪癫痫,小儿客忤,消食及冷气,并煎汁服之。” 3.《本草纲目》:“平肝去怯,治善怒发狂。”现代研究1.化学成分:生铁落主含四氧化三铁,或名磁性氧化铁(Fe3O4或FeO·Fe2O3)。2.药理作用:铁落经火煅醋淬后,变成醋酸铁,使易于吸收,且能促进红钿胞的新生和增加血红素的数值,有补血作用。并有一定的镇静作用。
煅磁石:辛咸,平,无毒;入肾经、肝经、肺经。《日华子本草》:“治眼昏,筋骨羸弱,补五劳七伤,除烦躁,消肿毒。”《名医别录》:“养肾藏,强骨气,益精除烦,通关节,消痈肿鼠瘘,颈核喉痛,小儿惊痫。”功能平肝潜阳,安神镇惊,聪耳明目,纳气平喘。主眩晕目花、耳聋、耳鸣、惊悸,失眠,肾虚喘逆。给大鼠静脉注射后,可使动物血液中血红蛋白水平、红细胞和白细胞数增加,血液凝固时间延长及血浆纤维蛋白分解活性增加,同时中性粒细胞吞噬反应增加。磁石炮制后镇静及抗惊厥作用明显增强。
乌梅:味苦、酸、涩,性温,入肝、肺、脾、大肠经,生津止渴,固精缩带缩尿,安蛔止痛。《本草拾遗》:“去痰,主疟瘴,止渴调中,除冷热痢,止吐逆。”《日华子本草》:“除劳,治骨蒸,去烦闷,涩肠止痢,消酒毒,治偏枯皮肤麻痹,去黑点,令人得睡。又入建茶、干姜为丸,止休息痢。”具有敛肺,涩肠,止血,生津的作用,用于治疗久痢不止,湿热泻痢,便血、尿血、雪崩等证。乌梅有消毒的功能,也防止食物在肠胃里腐化。乌梅里的苹果酸把适量的水分导引到大肠,形成粪便而排出体外。当血液净化时,新陈代谢就增强,身体自然会恢复能量。乌梅里的柠檬酸酸帮助吸收维他命及酵素,还有能预防疾病及消除疲劳。
五味子:性温,味酸、甘,归肺、心、肾经,收敛固涩,益气生津,补肾宁心的功效,用于久嗽虚喘,梦遗滑精,遗尿尿频,久泻不止,自汗,盗汗,津伤口渴,短气脉虚,内热消渴,心悸失眠等证。唐等《新修本草》载“五味皮肉甘酸,核中辛苦,都有咸味”,故有五味子之名。古医书称它荎蕏、玄及、会及,最早列于神农本草经上品,中药功效在于滋补强壮之力,药用价值极高,一般搭配硒制作养肝片和联苯双酯,双环醇片等,有保肝护肝功能。五味子分为2属,即南五味子属和五味子属。该树种易种植,粗生,成活率极高。具有收敛固涩,益气生津,补肾宁心的功效,用于久嗽虚喘,梦遗滑精,遗尿尿频,久泻不止,自汗,盗汗,津伤口渴,短气脉虚,内热消渴,心悸失眠等证。五味子具有消炎作用,以制止肝脏损伤,激活合成代谢过程以促进受损肝细胞的修复,并能增强脱氧核醣核酸(DNA)合成物和鸟胺酸脱羧酶的活性,再生肝脏细胞。
蚕蛹:甘、平。成分: 蛹含蛋白质、脂肪油,其中主要成分是不饱和脂肪酸、甘油醋,少量卵磷脂、淄醇、脂溶性维生素等。蚕砂 (蚕屎)含有机物,其中有蛋白质及叶绿素,并含植物生长激素及组氨酸。日光照射后的蚕砂,小鸡食后有钙化骨胳的功效,或系其所含维生素D前级物质属于2、1-二氢化钙醇之故。功效作用方面,蚕蛹是体弱、病后、老人及产妇产后的高级营养补品。蚕蛹能产生具有药理学活性物质,可有效提高人体内白细胞水平,从而提高免疫力、延缓衰老。蚕蛹油可以降血脂、降胆固醇,对治疗高胆固醇血症和改善肝功能有显著作用。蚕蛹炒食治劳瘦及小儿疳瘦,蚕蛹油对高血压、脂肪肝、高脂血症等有一定效果。白僵蚕治小儿惊痫夜啼,痉风撮口。晚蚕砂浸酒缓诸风,去顽痹。蚕茧治消渴,止血及治齿衄。
紫菜:味甘、咸,性凉。紫菜能抗辐射、抗突变、抗氧化,与其含硒有关。紫菜所含的多糖具有明显增强细胞免疫和体液免疫功能,可促进淋巴细胞转化,提高机体的免疫力;可显著降低进血清胆固醇的总含量,富含胆碱和钙、铁、能增强记忆、治疗妇女贫血、促进骨骼、牙齿的生长和保健;含有一定量的甘露醇,可作为治疗水肿的辅助食品,尤其适合甲状腺肿大、水肿、慢性支气管炎、咳嗽、瘿瘤、淋病、脚气、高血压、肺病初期、心血管病和各类肿块、增生的患者更宜食用。
龟甲:咸、甘,微寒;归肝、肾、心经。滋阴潜阳,益肾强骨,养血补心。《本草纲目》:“补心、补肾、补血,皆以养阴也……观龟甲所主诸病,皆属阴虚血弱。”滋阴潜阳,益肾强骨,养血补心。用于阴虚潮热,骨蒸盗汗,头晕目眩,虚风内动,筋骨痿软,心虚健忘。煎剂高浓度时对大鼠离体子宫有一定收缩作用;对人型结核杆菌有抑制作用;龟甲煎剂连续灌胃6天对大鼠内分泌系统有影响。龟甲能改善动物“阴虚”证病理动物机能状态,使之恢复正常;能增强免疫功能;具有双向调节DNA合成率的效应;对离体和在体子宫均有兴奋作用;有解热、补血、镇静作用;尚有抗凝血、增加冠脉流量和提高耐缺氧能力等作用;龟甲胶有一定提升白细胞数的作用。
鳖甲:咸、寒,归肝、肾经。滋肾潜阳,软坚散结。《药性论》:“主宿食、症块、痃癖气、冷瘕、劳瘦,下气,除骨热,骨节间劳热,结实壅塞。治妇人漏下五色赢瘦者。”主治骨蒸劳热、疟母、胁下坚硬、腰痛,经闭症瘕等症。鳖甲粉末口服280mg/kg对小鼠移植实质性癌MH134具有抑制作用,使肿瘤直径减小,肿瘤重量显著减轻。以0.5%或1.0%鳖多糖Renger液浸泡蟾蜍坐骨神经腓肠肌标本,有增加收缩高度和画纹面积、延长持续收缩时间的作用。该品能抑制结缔组织的增生,可消失结块;并具有增加血浆蛋白的作用,有谓可用于肝病所致的贫血。
浮小麦:甘咸,凉,归心经。《本草纲目》:“益气除热,止自汗盗汗,骨蒸劳热,妇人劳热。”《本经逢原》:"浮麦,能敛盗汗,取其散皮腠之热也。"除虚热,止汗。主止阴虚发热,盗汗,自汗。富含淀粉、蛋白质、脂肪、矿物质、钙、铁、硫胺素、核黄素、烟酸、维生素A及维生素C等。
海螵蛸:味咸、涩,性微温。归肝、肾经。性温,味甘微苦,归肝脾经。《本草纲目拾遗》:“和血,行血,理气。治风痹。”《本草再新》:“舒肝胆之郁气,健脾降火。治腹中冷痛,胃脘积寒,兼能破血。”利气、行血,治风痹,散疲止痛。《本草纲目》:“主女子血枯病,伤肝,唾血下血,治疟消瘿。海螵蛸研末敷小儿疳疮,痘疮臭烂,丈夫阴疮,汤火伤,跌伤出血。”功效收敛止血、固精止带、制酸敛疮。乌贼骨中所含的碳酸钙,可作止酸剂。生海螵蛸长于固精止带、制酸。常用于梦遗滑精,赤白带下,胃痛吐酸。炒后矫味臭,收涩之性增强,长于收敛止血,止带,敛疮。可用于崩漏下血,创伤出血,赤白带下,疮疡湿疹。
香橼:味辛、甘,无毒。疏肝理气,宽胸化痰,除湿和中。主治下气,除心头痰水。煮酒喝,治痰气咳嗽。《本草通玄》:“理上焦之气,止呕逆,进食,健脾。”《本草再新》:“平肝舒郁,理肺气,通经利水,治腰脚气。”功用疏肝理气,宽胸化痰,除湿和中。主治下气,除心头痰水。煮酒喝,治痰气咳嗽。煎水,治心下气痛。根叶皮相同。该品辛能行散,苦能疏泄,入肝经而能疏理肝气而止痛。治肝郁胸胁胀痛,气香醒脾,辛行苦泄,入脾胃以行气宽中。用治脾胃气滞之脘腹胀痛,该品苦燥降泄以化痰止咳,辛行入肺而理气宽胸。用治痰多、咳嗽、胸闷等。该品所含的橙皮甙对豚鼠因缺乏维生素C而致的眼睛球结膜血管内细胞凝聚及毛细血管抵抗力降低有改善作用,能降低马血细胞之凝聚。橙皮甙有预防冻伤和抑制大鼠晶状体的醛还原酶作用。黄柏酮有增强离体兔肠张力和振幅的作用。
核桃仁:味甘,性温,入肾、肺、大肠经,具有补肾益精,温肺定喘,润肠通便的作用,用于肾气亏虚之腰痛腿软,头晕乏力,尿频遗精,消渴,肺肾两虚之咳喘,老年人气虚及产后血亏津少而致的肠燥便秘,跌打损伤,疮疡痈肿等证。核桃中的磷脂,对脑神经有很好保健作用。核桃油含有不饱和脂肪酸,有防治动脉硬化的功效。核桃仁中含有锌、锰、铬等人体不可缺少的微量元素。人体在衰老过程中锌、锰含量日渐降低,铬有促进葡萄糖利用、胆固醇代谢和保护心血管的功能。核桃仁的镇咳平喘作用也十分明显,冬季,对慢性气管炎和哮喘病患者疗效极佳。
松子:甘,温。润肺,滑肠。用于肺燥咳嗽,慢性便秘。松子具有滋阴润燥、扶正补虚的功效,特别适合体虚、便秘、咳嗽等病患者食用。特别值得一提的是,松子的通便作用温和,因而特别适合年老体弱、病后、产后的便秘者食用。如可取松子仁20克碾碎,同粳米100克煮粥,分早晚服食。松子是大脑的优质营养补充剂,特别适合用脑过度人群食用。松子中所含的不饱和脂肪酸具有增强脑细胞代谢,维护脑细胞功能和神经功能的作用。谷氨酸含量高达16.3%,谷氨酸有很好的健脑作用,可增强记忆力。
鸡内金:味甘,性寒,入脾、胃、小肠、膀胱经,《日华子本草》:“止泄精,并尿血、崩中、带下、肠风、泻痢。”《滇南本草》:“宽中健脾,消食磨胃。治小儿乳食结滞,肚大筋青,痞积疳积。”有健脾消食、涩精止溺的作用,主要用于食积停滞之脘腹胀满,暖气腹泻,小儿疳疾等症状,鸡内金能促进胃液分泌、增强胃蠕动、加速胃排空等作用。
熟地:味甘,性微温,入肝、肾经,补肾填精,养血和阴,养阴生髓,补五脏内伤不足,通血脉,利耳目,黑须发,男子五劳七伤,女子伤中胞漏,经候不调,胎产百病。《本草纲目》:“填骨髓,长肌肉,生精血。补五脏内伤不足,通血脉,利耳目,黑须发,男子五劳七伤,女子伤中胞漏,经候不调,胎产百病。”具有补血滋阴,益精填髓的作用,用于血虚萎黄;眩晕,心悸,失眠,月经不调,崩不止;肝肾阴亏,盗汗,足膝疼痛,腰膝酸软,耳鸣耳聋,头目昏花,遗精阳痿,不育不孕,月经不调,崩漏下血,须发早白,消渴,肾虚喘促等证。
何首乌:苦、甘、涩,微温;归肝,肾经。主治肝肾精血不足,腰膝酸软,遗精耳鸣,头晕目眩。《本草汇言》:“有微毒。入通于肝,外合于风,升也,阳也。”《开宝本草》:“本出顺州南河县,今岭外江南诸州皆有。蔓紫,花黄白,叶如薯蓣而不光。生必相对,根大如拳,有赤、白两种,赤者雄,白者雌,…春、夏采。”可解毒,消痈,润肠通便。主治肝肾精血不足,腰膝酸软,遗精耳鸣,头晕目眩,心悸失眠,须发早白,脾燥便秘,风疹癣疥,皮肤瘙痒,疟疾,瘰疬,脾性风,痔疮,疮痈。具有促进造血功能,增强免疫功能,降血脂与抗动脉粥样硬化,保肝,何首乌含有大黄酚、大黄素、大黄酸、大黄素甲醚、脂肪油、淀粉、糖类、土大黄甙、卵磷脂等有效成分。药理研究证明,何首乌能促进人体淋巴母细胞的转化。尚有降低血清胆固醇、抗动脉硬化、抗光毒等作用。
阿胶:味甘平,入肺、肝、肾经,具有补血止血、滋阴润燥等功效,用于血虚萎黄,眩晕心悸,心烦不眠,肺燥咳嗽。凡治喘嗽,不论肺虚、肺实,可下可温,须用阿胶以安肺润肺,其性和平,为肺经要药。小儿惊风后瞳人不正者,以阿胶倍人参煎服最良,阿胶育神,人参益气也。又痢疾多因伤署伏热而成,阿胶乃大肠之要药,有热毒留滞者,则能疏导,无热毒留滞者,则能平安。数说足以发明阿胶之蕴矣。
砂仁:味辛,性温;归脾经、胃经、肾经。化湿开胃,温脾止泻,理气安胎。《汤液本草》:“缩砂,与白檀、豆蔻为使则入肺,与人参、益智为使则入脾,与黄柏、茯苓为使则入肾,与赤、白石脂为使则入大、小肠。”《日华子本草》:“治一切气,霍乱转筋,心腹痛。”功能化湿开胃,温脾止泻,理气安胎。用于湿浊中阻,脘痞不饥,脾胃虚寒,呕吐泄泻,妊娠恶阻,胎动不安。该品辛散温通,气味芬芳,其化湿醒脾,行气温中之效均佳,古人曰其:“为醒脾调胃要药。”故凡湿阻或气滞所致之脘腹胀痛等脾胃不和诸证常用,尤其是寒湿气滞者最为适宜。该品善能温中暖胃以达止呕止泻之功,但其重在温脾。
翼核果:别名血风根、血风藤、红蛇根、青筋藤、铁牛入石、拉牛入石。来源鼠李科翼核果属植物翼核果Ventilago leiocarpa Benth.,以根入药。全年可采,洗净切片,晒干。性味苦,温。功能主治养血祛风,舒筋活络。用于风湿筋骨痛,跌打损伤,腰肌劳损,贫血头晕,四肢麻木,月经不调。
一点血:生于溪边或阴湿石岩上。在四川有分布。化学成份根状茎显强心甙、黄酮类、鞣质、酚类、甾醇、三萜类、皂甙反应。性味甘、苦,平。功能主治补气健脾,养血、止血。病后虚弱,咳嗽咯血,功能性子宫出血,白带。
白术:味甘、苦,性温,入脾、胃经,有补脾利气,燥湿利水,固表止汗,运脾润燥的功效,主治脾失健运、气不化水所致之痞满腹泻,痰饮水肿;中气不足之心烦懒言,崩中漏下,久痢脱肛;脾虚气弱之奏里不固、虚汗自汗等证,白术能促进胃液分泌,增强小肠的吸收作用,对胃肠功能有调节作用。具有明显而持久的利尿作用,对各种动物如大鼠、兔、狗都有作用。对不麻醉狗静脉注射煎剂0.05-0.25g/kg,尿量增加可达9倍以上,并在用药5小时后仍高于正常。白术对血小板聚集有明显的抑制作用,白术煎剂0.5g/kg灌胃l-4周,能显著延长大鼠凝血酶元的时间。白术有血管扩张作用。对心脏呈抑制作用,剂量过大时可致停博,麻醉犬静脉注射煎剂0.1g/kg,血压轻度下降0.25g/kg时,血压急剧下降,3-4小时内未见恢复。
人参:性平、味甘、微苦,微温。归脾、肺经、心经。功用大补元气,复脉固脱,补脾益肺,生津止渴,安神益智。主治劳伤虚损、食少、倦怠、反胃吐食、大便滑泄、虚咳喘促、自汗暴脱、惊悸、健忘、眩晕头痛、阳痿、尿频、消渴、妇女崩漏、小儿慢惊及久虚不复,一切气血津液不足之症。人参能调节中枢神经系统兴奋过程和抑制过程的平衡。对学习记忆的影响有双向性及成分依赖性,具有中枢拟胆碱活性和拟儿茶酚胺活性,能增强胆碱系统功能,增加 Ach 的合成和释放,同时提高中枢M-胆碱受体密度。人参抗疲劳作用的机制可能与其升高血脂和促进蛋白质、RNA 合成有关。同时人参活性物质还具有抑制黑色素的还原性能,使皮肤洁白光滑。它的美容效用数不胜数,是护肤美容的极品。
黄芪:甘,微温;归肺、脾、肝、肾经。补气健脾,益卫实表,升阳举陷,托毒敛疮,利水消肿。《本草备要》:“黄芪,生用固表,无汗能发,有汗能止;炙用补中,益元气,壮脾胃。生血,生肌,排脓内托,疮痈圣药。痘症不起,阳虚无热者宜之。”《本草正义》:“黄芪,补益中土,温养脾胃,凡中气不振,脾土虚弱,清气下陷者最宜。其皮直达人之肤表肌肉,固护卫阳,充实表分,是其专长,所以表虚诸病,最为神剂。”功用固表敛汗,利水消肿,托疮排脓,通调水道。黄芪使心脏收缩能力增强,能改善全身的血液循环,能扩张冠状动脉、肾血管及拳参末梢血管、使皮肤血液循环旺盛;能提高机体的非特异免疫力,有保肝和降低血糖的作用,对葡萄球菌、血溶性链球菌、肺炎双球菌、痢疾杆菌等有抑制作用。黄芪可显著影响脾淋巴细胞信息传导,实现免疫调节作用。可用于高血压病,缺血性心脏病,急性肾小球肾炎,胃溃疡,银屑病,糖尿病,骨质疏松。
当归:味甘、辛、苦,性温,入肝、心、脾经,补血和血,活血通络,润肠通便。《注解伤寒论》:“脉者血之府,诸血皆属心,凡通脉者必先补心益血,故张仲景治手足厥寒,脉细欲绝者,用当归之苦温以助心血。”《本草新编》:“当归,味甘辛,气温,可升可降,阳中之阴,无毒。虽有上下之分,而补血则一。入心、脾、肝三脏。但其性甚动,入之补气药中则补气,入之补血药中则补血,无定功也。”具有补血活血,调经止痛、润汤通便的作用,用于血虚萎黄、眩晕心悸、月经不调、经闭痛经、虚寒腹痛、肠燥便秘、风湿痹痛、跌扑损伤、痈疽疮疡等证。①抗缺氧作用;②调节机体免疫功能、具有抗癌作用;③护肤美容作用;④补血活血作用;⑤抑菌、抗动脉硬化作用。现代研究表明,当归具有调节机体免疫功能、补血活血,抑菌等作用。其能改善子宫的血液循环、减轻盆腔充血,缓解痛经,此外,当归能够增强机体的免疫力。
桑鳸:群栖于山区混交林中或平原杂林中。食物为野生植物的种子及浆果和鳞芽等。分布我国东北部,迁徙时经河北、河南、江苏、四川等地至南部越冬。性味《纲目》:"甘,温,无毒。"功能主治治虚损羸瘦。①汪颖《食物本草》:"主肌肉虚羸,益皮肤。"②《东医宝鉴》:"炙食,能补气。"③《随息居饮食谱》:"补胃。"
牛尾菜:性味甘苦,平。①《江西草药》:"性温,味甘微苦。"②《贵州草药》:"性平,味甘。"③《陕西中草药》:"味苦,性平。"功能主治补气活血,舒筋通络。治气虚浮肿,筋骨疼痛,偏瘫,头晕头痛,咳嗽吐血,骨结核,白带。①《江西草药》:"祛风散瘀。治风湿痹痛,跌打损伤。"②《贵州草药》:"清热止咳,补虚益损。"③《陕西中草药》:"祛风湿,活血通络,消炎镇痛。治风湿性关节炎,筋骨疼痛,高血压所致之偏瘫,骨髓炎,骨结核。"④金华《常用中草药单方验方选编》:"治白带过多,淋巴结炎。"⑤《湖南药物志》:"舒筋活血,补气通络。"
以下采用实施例来详细说明本发明的实施方式,借此对本发明如何应用技术手段来解决技术问题,并达成技术效果的实现过程能充分理解并据以实施。
实施例1 散剂
甘草25份、茯神20份、远志15份、酸枣仁25份、木香8份、龙眼肉26份、大枣30份、生铁落18份、磁石15份、乌梅14份、五味子20份、蚕蛹26份、紫菜30份、龟甲12份、鳖甲12份、浮小麦20份、海螵蛸23份、香橼20份、核桃仁30份、松子24份、鸡内金19份、熟地23份、何首乌20份、阿胶35份、砂仁16份、翼核果24份、一点血20份。
其制备过程为:
第一步,将所述原料药材按比例混合,加入相对于混合物质量3倍的醇浓度为80%的乙醇,加热回流1小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量1倍的醇浓度为80%的乙醇,加热回流1小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1小时,粉碎,过筛,获得300目的超微细粉;
第三步,在将第二步获得的超微细粉中加入相对于其质量2倍的淀粉,混合,获得散剂。
实施例2 颗粒剂
甘草25份、茯神20份、远志15份、酸枣仁25份、木香8份、龙眼肉26份、大枣30份、生铁落18份、磁石15份、乌梅14份、五味子20份、蚕蛹26份、紫菜30份、龟甲12份、鳖甲12份、浮小麦20份、海螵蛸23份、香橼20份、核桃仁30份、松子24份、鸡内金19份、熟地23份、何首乌20份、阿胶35份、砂仁16份、翼核果24份、一点血20份、白术18份、人参16份、黄芪15份、当归20份、桑鳸20份、牛尾菜20份。
其制备过程为:
步骤一:将所述原料药材按所述比例混合,加相对于混合物3倍的醇浓度为84%的乙醇,加热至沸腾回流2小时,过滤,采用渗漉法以每分钟1ml的速度缓缓渗漉,收集渗漉液,随后在真空度0.06Mpa下减压浓缩至55℃时相对密度为1.04的膏体,喷雾干燥,喷雾干燥机的进风温度165℃、出风温度80℃,随后粉碎成粉末,制成干膏粉;
步骤二:在获得的干膏粉中加入相对于干膏粉质量0.1倍的蔗糖粉和0.3倍的糊精,制成颗粒,于45℃干燥,获得颗粒剂。
实施例3 片剂
甘草15重量份、茯神15重量份、远志14重量份、酸枣仁15重量份、木香6重量份、龙眼肉20重量份、大枣25重量份、生铁落15重量份、磁石13重量份、乌梅12重量份、五味子17重量份、蚕蛹22重量份、紫菜25重量份、龟甲7重量份、鳖甲8重量份、浮小麦17重量份、海螵蛸19重量份、香橼15重量份、核桃仁25重量份、松子20重量份、鸡内金15重量份、熟地17重量份、何首乌17重量份、阿胶28重量份、砂仁14重量份、翼核果17重量份、一点血18重量份、白术16重量份、人参14重量份、黄芪13重量份、当归17重量份、桑鳸16重量份、牛尾菜17重量份。
其制备过程为:
第一步,将所述原料药材按比例混合,加入相对于混合物质量4倍的醇浓度为85%的乙醇,加热回流3小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量2倍的醇浓度为85%的乙醇,加热回流3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎2小时,粉碎,过筛,获得350目的超微细粉;
第三步,将第二步获得的超微细粉,加入相对于其质量0.1倍的微晶纤维素、0.08倍乳糖、0.1倍的淀粉,过筛,混合均匀,制粒,干燥,加入相对于超微细粉质量0.005倍硬脂酸镁,整粒,压片,制成。
药物组合物的毒性试验
①试验药物:
试验药物一:将原料药材甘草10份、茯神10份、远志10份、酸枣仁10份、木香5份、龙眼肉15份、大枣20份、生铁落10份、磁石10份、乌梅10份、五味子10份、蚕蛹13份、紫菜20份、龟甲7份、鳖甲6份、浮小麦10份、海螵蛸12份、香橼10份、核桃仁20份、松子18份、鸡内金10份、熟地12份、何首乌13份、阿胶25份、砂仁10份、翼核果12份、一点血10份混合放入紫砂锅中,加入清水,至清水浸过药材上表面5cm,浸泡7小时;将紫砂锅置于火上,武火煮沸后,改用文火慢煎30分钟至药液的剂量为300ml,过滤,得滤液a,备用;将剩余药渣再次加入清水,至清水浸过药材上表面3cm,浸泡10小时;将紫砂锅置于火上,武火煮沸后,改用文火慢煎25分钟至药液的剂量为300ml,过滤,得滤液b,将滤液a和滤液b混合得汤剂。
试验药物二:将甘草25重量份、茯神20重量份、远志15重量份、酸枣仁25重量份、木香8重量份、龙眼肉26重量份、大枣30重量份、生铁落18重量份、磁石15重量份、乌梅14重量份、五味子20重量份、蚕蛹26重量份、紫菜30重量份、龟甲12重量份、鳖甲12重量份、浮小麦20重量份、海螵蛸23重量份、香橼20重量份、核桃仁30重量份、松子24重量份、鸡内金19重量份、熟地23重量份、何首乌20重量份、阿胶35重量份、砂仁16重量份、翼核果24重量份、一点血20重量份、白术18重量份、人参16重量份、黄芪15重量份、当归20重量份、桑鳸20重量份、牛尾菜20重量份混合放入紫砂锅中,加入清水,至清水浸过药材上表面5cm,浸泡5小时;将紫砂锅置于火上,武火煮沸后,改用文火慢煎50分钟至药液的剂量为300ml,过滤,得滤液a,备用;将剩余药渣再次加入清水,至清水浸过药材上表面3cm,浸泡10小时;将紫砂锅置于火上,武火煮沸后,改用文火慢煎35分钟至药液的剂量为300ml,过滤,得滤液b,将滤液a和滤液b混合得汤剂。
②试验方法:
方法一:急性毒性试验:选择20只生命体征相同的白鼠,以试验药物一为对象,临床日用量的150倍给白鼠大肠内投药,观察7日。结果所有白鼠健存,其活动、饮食、毛发、排泄物未发现异常,未见毒性反应。对白鼠阴道和破损皮肤进行刺激性试验,未见有刺激性反应和其它不良反应。毒性试验证明,本试验药物一不具有毒性作用和不良反应,临床应用安全可靠。
方法二:蓄积毒性试验:选用20只健康小白鼠,雌、雄各10只,以试验药物二为对象,剂量设计每5天为一期,每期剂量分别为0.10LD50 、0.15LD50 、0.22LD50 、0.34LD 50 、0.50LD50 ,此样品的雌性、雄性小鼠的LD 50均为5000m份/k份BW(五个剂量为500、750、1100、1700、2500m份/k份BW)。每5天称体重一次,调整给药量,按0.1ml/10份BW经口灌胃。20天后,小白鼠无死亡情况发生,试验结束,按递增剂量给受试物20天后,雌性、雄性动物均无死亡情况发生。证明,本试验药物二没有蓄积毒性,临床应用安全可靠。
对比试验
山东某养猪场养殖猪约2000头,育有仔猪1400头,2013年4月,约有500头仔猪出现营养不良性贫血的症状:病猪精神沉郁,离群伏卧,食欲减退,被毛逆立,缺乏光泽,生长缓慢或停止。体温不高,多伴腹泻。可视粘膜色淡,轻度黄染或苍白。光照耳壳呈灰白色,几乎见不到明显的血管,针刺也很少出血。呼吸增数,脉搏急速,可听到贫血性心内杂音;轻微运动则心搏动强盛,喘息不止。头和前躯可发生水肿,有时发生膈痉挛。有的仔猪外观很肥胖,生长发育也较快,可在奔跑中突然死亡。有的仔猪外观消瘦,便秘下痢交替出现,异嗜,衰竭;腹壁卷缩,其体型呈橄榄状。
选择200头患病仔猪,隔离养殖,并随机分为四组,实施例1组、实施例2组、实施例3组和对照组,每组50头。
实施例1组采用本发明实施例1的药物组合物散剂进行治疗,将散剂按照3:100的比例混入传统仔猪饲料中,正常饲喂,进行10日。
实施例2组采用本发明实施例2的药物组合物颗粒剂进行治疗,将颗粒剂按照3:100的比例混入传统仔猪饲料中,正常饲喂,进行10日。
实施例3组采用本发明实施例3的药物组合物片剂进行治疗,将片剂按照3:100的比例混入传统仔猪饲料中,正常饲喂,进行10日。
对照组:用硫酸亚铁2.5g、氯化钴2.5g、硫酸铜1g,冷开水加至1000ml,混合后用纱布滤过,1Kg体重用0.25ml,涂于母猪乳头上,或混于仔猪饲料及饮水中,每日1次,连服进行10日。
记录实验过程的治疗情况。参见表1。
记录实验前后的仔猪的平均体重,计算出平均体重增长情况。参见表2。
表1为各组的治疗情况对比(总共50头)
参见表1可以看出,实施例1组、实施例2组和实施例3组的治疗仔猪的治愈数和治愈率都要高于对照组的仔猪的治愈数和治愈率,可以得知,本发明的药物组合物,治疗仔猪营养不良性贫血上,治疗效果好,疗效确切,很好的改善病情。
表2为各组的仔猪的平均增长体重对比
参见表2可以看出,实施例1组、实施例2组和实施例3组的治疗仔猪营养不良性贫血的同时,增长速度都要快于对照组,保持了仔猪的正常生长。
综上所述,本发明药物组合物,在治疗仔猪营养不良性贫血上,治疗效果好,疗效确切,并且保证了仔猪的正常生长。
举例:德州市某养猪场育有仔猪1000头,2013年8月,200头出现仔猪营养不良性贫血的症状:病猪精神沉郁,离群伏卧,食欲减退,被毛逆立,缺乏光泽,生长缓慢或停止。体温不高,多伴腹泻。可视粘膜色淡,轻度黄染或苍白。光照耳壳呈灰白色,几乎见不到明显的血管,针刺也很少出血。呼吸增数,脉搏急速,可听到贫血性心内杂音;轻微运动则心搏动强盛,喘息不止。头和前躯可发生水肿,有时发生膈痉挛。有的仔猪外观很肥胖,生长发育也较快,可在奔跑中突然死亡。有的仔猪外观消瘦,便秘下痢交替出现,异嗜,衰竭;腹壁卷缩,其体型呈橄榄状。选择80头患病仔猪进行隔离治疗,选择实施例2的药物组合物颗粒剂,按照3:100的比例混入传统仔猪饲料中进行正常饲喂,治疗10日,有效的为76头,有效率95%。体重在治疗期间增长6.3kg。
以上所述仅为本发明的较佳实施例,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种用于治疗仔猪营养不良性贫血的药物组合物,其特征在于,所述药物组合物包括以下原料药材:甘草、茯神、远志、酸枣仁、木香、龙眼肉、大枣、生铁落、磁石、乌梅、五味子、蚕蛹、紫菜、龟甲、鳖甲、浮小麦、海螵蛸、香橼、核桃仁、松子、鸡内金、熟地、制何首乌、阿胶、砂仁、翼核果、一点血。
2.根据权利要求1所述的用于治疗仔猪营养不良性贫血的药物组合物,其特征在于,所述药物组合物中各原料药材的重量份数为:甘草10-25重量份、茯神10-20重量份、远志10-15重量份、酸枣仁10-25重量份、木香5-8重量份、龙眼肉15-26重量份、大枣20-30重量份、生铁落10-18重量份、磁石10-15重量份、乌梅10-14重量份、五味子10-20重量份、蚕蛹13-26重量份、紫菜20-30重量份、龟甲7-12重量份、鳖甲6-12重量份、浮小麦10-20重量份、海螵蛸12-23重量份、香橼10-20重量份、核桃仁20-30重量份、松子18-24重量份、鸡内金10-19重量份、熟地12-23重量份、何首乌13-20重量份、阿胶25-35重量份、砂仁10-16重量份、翼核果12-24重量份、一点血10-20重量份。
3.根据权利要求1或2所述的用于治疗仔猪营养不良性贫血的药物组合物,其特征在于,所述药物组合物中各原料药材的重量份数为:甘草25重量份、茯神20重量份、远志15重量份、酸枣仁25重量份、木香8重量份、龙眼肉26重量份、大枣30重量份、生铁落18重量份、磁石15重量份、乌梅14重量份、五味子20重量份、蚕蛹26重量份、紫菜30重量份、龟甲12重量份、鳖甲12重量份、浮小麦20重量份、海螵蛸23重量份、香橼20重量份、核桃仁30重量份、松子24重量份、鸡内金19重量份、熟地23重量份、何首乌20重量份、阿胶35重量份、砂仁16重量份、翼核果24重量份、一点血20重量份。
4.根据权利要求1-3任一项所述的用于治疗仔猪营养不良性贫血的药物组合物,其特征在于,所述药物组合物还包括白术、人参、黄芪、当归、桑鳸、牛尾菜。
5.根据权利要求1-4任一项所述的用于治疗仔猪营养不良性贫血的药物组合物,其特征在于,所述药物组合物中各原料药材的重量份数为:甘草10-25重量份、茯神10-20重量份、远志10-15重量份、酸枣仁10-25重量份、木香5-8重量份、龙眼肉15-26重量份、大枣20-30重量份、生铁落10-18重量份、磁石10-15重量份、乌梅10-14重量份、五味子10-20重量份、蚕蛹13-26重量份、紫菜20-30重量份、龟甲7-12重量份、鳖甲6-12重量份、浮小麦10-20重量份、海螵蛸12-23重量份、香橼10-20重量份、核桃仁20-30重量份、松子18-24重量份、鸡内金10-19重量份、熟地12-23重量份、何首乌13-20重量份、阿胶25-35重量份、砂仁10-16重量份、翼核果12-24重量份、一点血10-20重量份、白术10-18重量份、人参12-16重量份、黄芪10-15重量份、当归13-20重量份、桑鳸10-20重量份、牛尾菜14-20重量份。
6.根据权利要求1-5任一项所述的用于治疗仔猪营养不良性贫血的药物组合物,其特征在于,所述药物组合物中各原料药材的重量份数为:甘草25重量份、茯神20重量份、远志15重量份、酸枣仁25重量份、木香8重量份、龙眼肉26重量份、大枣30重量份、生铁落18重量份、磁石15重量份、乌梅14重量份、五味子20重量份、蚕蛹26重量份、紫菜30重量份、龟甲12重量份、鳖甲12重量份、浮小麦20重量份、海螵蛸23重量份、香橼20重量份、核桃仁30重量份、松子24重量份、鸡内金19重量份、熟地23重量份、何首乌20重量份、阿胶35重量份、砂仁16重量份、翼核果24重量份、一点血20重量份、白术18重量份、人参16重量份、黄芪15重量份、当归20重量份、桑鳸20重量份、牛尾菜20重量份。
7.根据权利要求1-6任一项所述的用于治疗仔猪营养不良性贫血的药物组合物,其特征在于,所述药物组合物的剂型为散剂,其制备方法包括以下步骤:
第一步,将所述原料药材按比例混合,加入相对于混合物质量3~5倍的醇浓度为80~90%的乙醇,加热回流1~3小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量1~2倍的醇浓度为80~90%的乙醇,加热回流1~3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1~2小时,粉碎,过筛,获得300目~400目的超微细粉;
第三步,在将第二步获得的超微细粉中加入相对于其质量2~4倍的淀粉,混合,获得散剂。
8.根据权利要求1-6任一项所述的用于治疗仔猪营养不良性贫血的药物组合物,其特征在于,所述药物组合物的剂型为颗粒剂,其制备方法包括以下步骤:
步骤一:将所述原料药材按所述比例混合,加相对于混合物3~6倍的醇浓度为84%~90%的乙醇,加热至沸腾回流2~4小时,过滤,采用渗漉法以每分钟1~2ml的速度缓缓渗漉,收集渗漉液,随后在真空度0.06~0.09Mpa下减压浓缩至55~60℃时相对密度为1.04~1.12的膏体,喷雾干燥,喷雾干燥机的进风温度165~175℃、出风温度80~85℃,随后粉碎成粉末,制成干膏粉;
步骤二:在获得的干膏粉中加入相对于干膏粉质量0.1~0.3倍的蔗糖粉和0.1~0.3倍的糊精,制成颗粒,于45~50℃干燥,获得颗粒剂。
9.一种如权利要求1-6任一项所述的用于治疗仔猪营养不良性贫血的药物组合物的制备方法,其特征在于,所述药物组合物的剂型为散剂,其制备方法包括以下步骤:
第一步,将所述原料药材按比例混合,加入相对于混合物质量3~5倍的醇浓度为80~90%的乙醇,加热回流1~3小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量1~2倍的醇浓度为80~90%的乙醇,加热回流1~3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1~2小时,粉碎,过筛,获得300目~400目的超微细粉;
第三步,在将第二步获得的超微细粉中加入相对于其质量2~4倍的淀粉,混合,获得散剂。
10.一种如权利要求1-6任一项所述的用于治疗仔猪营养不良性贫血的药物组合物的制备方法,其特征在于,所述药物组合物的剂型为颗粒剂,其制备方法包括以下步骤:
步骤一:将所述原料药材按所述比例混合,加相对于混合物3~6倍的醇浓度为84%~90%的乙醇,加热至沸腾回流2~4小时,过滤,采用渗漉法以每分钟1~2ml的速度缓缓渗漉,收集渗漉液,随后在真空度0.06~0.09Mpa下减压浓缩至55~60℃时相对密度为1.04~1.12的膏体,喷雾干燥,喷雾干燥机的进风温度165~175℃、出风温度80~85℃,随后粉碎成粉末,制成干膏粉;
步骤二:在获得的干膏粉中加入相对于干膏粉质量0.1~0.3倍的蔗糖粉和0.1~0.3倍的糊精,制成颗粒,于45~50℃干燥,获得颗粒剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410694360.6A CN104474440A (zh) | 2014-11-27 | 2014-11-27 | 用于治疗仔猪营养不良性贫血的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410694360.6A CN104474440A (zh) | 2014-11-27 | 2014-11-27 | 用于治疗仔猪营养不良性贫血的药物组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104474440A true CN104474440A (zh) | 2015-04-01 |
Family
ID=52749141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410694360.6A Withdrawn CN104474440A (zh) | 2014-11-27 | 2014-11-27 | 用于治疗仔猪营养不良性贫血的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104474440A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104940785A (zh) * | 2015-06-11 | 2015-09-30 | 山东新希望六和集团有限公司 | 用于防治仔猪营养不良性贫血的药物组合物及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103652361A (zh) * | 2013-12-23 | 2014-03-26 | 山东新希望六和集团有限公司 | 一种产后1-20天哺乳期母猪饲料及其制备方法 |
CN103690919A (zh) * | 2013-12-23 | 2014-04-02 | 山东新希望六和集团有限公司 | 用于治疗仔猪缺铁性贫血的药物及其制备方法 |
CN104381691A (zh) * | 2014-11-27 | 2015-03-04 | 山东新希望六和集团有限公司 | 用于预防仔猪营养不良性贫血的功能性饲料及其制备方法 |
-
2014
- 2014-11-27 CN CN201410694360.6A patent/CN104474440A/zh not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103652361A (zh) * | 2013-12-23 | 2014-03-26 | 山东新希望六和集团有限公司 | 一种产后1-20天哺乳期母猪饲料及其制备方法 |
CN103690919A (zh) * | 2013-12-23 | 2014-04-02 | 山东新希望六和集团有限公司 | 用于治疗仔猪缺铁性贫血的药物及其制备方法 |
CN104381691A (zh) * | 2014-11-27 | 2015-03-04 | 山东新希望六和集团有限公司 | 用于预防仔猪营养不良性贫血的功能性饲料及其制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104940785A (zh) * | 2015-06-11 | 2015-09-30 | 山东新希望六和集团有限公司 | 用于防治仔猪营养不良性贫血的药物组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102091258B (zh) | 一种祛除疤痕的中药组合物及其制备方法 | |
CN103520578B (zh) | 一种治疗口腔溃疡的中药组合物及其制备方法 | |
CN104381691A (zh) | 用于预防仔猪营养不良性贫血的功能性饲料及其制备方法 | |
CN101797326B (zh) | 一种治疗肠鸣腹泻的中药制剂及其制备方法 | |
CN103417904B (zh) | 一种治疗慢性唇炎的中药组合物及其制备方法 | |
CN103690919B (zh) | 用于治疗仔猪缺铁性贫血的药物及其制备方法 | |
CN103638250B (zh) | 一种治疗面神经麻痹的中药制剂及其制备方法 | |
CN105232911B (zh) | 一种中药组合物 | |
CN104013868B (zh) | 一种治疗慢性阻塞性肺疾病的中药组合物及其制备方法 | |
CN103877247B (zh) | 用于治疗褥疮的药物及其制备方法 | |
CN104127813A (zh) | 一种治疗气血两虚型褥疮的中药组合物及其制备方法 | |
CN104208623A (zh) | 具有妇女产后强身作用的瑶族洗浴药物及其制备方法 | |
CN104042891A (zh) | 缓解产妇大便秘结的中药组合物及其制备方法 | |
CN104274754A (zh) | 一种治疗小儿遗尿的中药组合物及其制备方法 | |
CN104206595A (zh) | 一种降脂降糖的地骨皮保健茶及其制备方法 | |
CN103989957A (zh) | 用于治疗胃阴亏虚型慢性胃炎的药物组合物及其制备方法 | |
CN105232987A (zh) | 一种促进神经外科术后康复的中药 | |
CN104800771A (zh) | 一种用于儿童夜惊症的中药制剂及其制备方法 | |
CN103920011A (zh) | 用于产后肝郁气滞型缺乳的药物组合物及其制备方法 | |
CN103933538A (zh) | 用于治疗脾肾阳虚型肝硬化腹水的药物及其制备方法 | |
CN102091254B (zh) | 一种用于面部整容后消肿的中药组合物及其制备方法 | |
CN105435190A (zh) | 用于治疗寒热错杂型哮病的中药组合物及其制备方法 | |
CN104474440A (zh) | 用于治疗仔猪营养不良性贫血的药物组合物及其制备方法 | |
CN104689240A (zh) | 一种治疗气滞血瘀型黄褐斑的药物及其制备方法 | |
CN103861075A (zh) | 用于治疗失眠的中药及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20150401 |